All the news Showing 10 of 368 articles from: Hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Models can help predict liver cancer in people cured of hepatitis C Liz Highleyman / 17 September 2020 Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ... Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Immunotherapy combinations show promise for advanced liver cancer Liz Highleyman / 02 September 2020 Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ... Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... Bulevirtide shows promise as maintenance therapy for hepatitis D Liz Highleyman / 30 August 2020 High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ... JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Liver cancer risk after hepatitis C cure is lower in people with HIV Keith Alcorn / 24 August 2020 People with HIV who were cured of hepatitis C were less likely than HIV-negative people to develop hepatocellular carcinoma (HCC – liver cancer) in the three-and-a-half years after completing hepatitis C treatment, Spanish ... New WHO guidance on preventing mother-to-child transmission of hepatitis B Keith Alcorn / 28 July 2020 Pregnant women who test positive for hepatitis B infection and have a high level of hepatitis B virus (HBV) in the blood should receive preventive antiviral therapy with tenofovir from the 28th week ... New method developed for non-invasive risk assessment following hepatitis C recovery Medical University of Vienna / 27 July 2020 ← Prev1...34567...37Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive